Published on 3 Jan 2024 on Zacks via Yahoo Finance
Shares of C4 Therapeutics, Inc. CCCC or C4T have skyrocketed 310.1% in the past three months compared with the industry’s increase of 9.8%.
The clinical-stage biopharmaceutical company is engaged in developing a new generation of medicines that harness targeted protein degradation. C4T utilizes its proprietary TORPEDO platform to design, analyze and predict degrader performance.
In December 2023, CCCC entered into an exclusive licensing and collaboration agreement with pharma giant Merck MRK to discover and develop degrader-antibody conjugates (“DACs”) with an initial focus on one oncology target.